FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
Autor: | Jorge Ignacio, Jin Soo Lee, Chong-Jen Yu, Yi-Long Wu, Li Zhang, Michael R. Johnston, Tony Mok, Yuh Min Chen, Kate Jin, Caicun Zhou |
---|---|
Rok vydání: | 2008 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment non-small cell lung cancer (NSCLC) Stage iiib medicine.disease respiratory tract diseases Double blind First line treatment G1 arrest Internal medicine Medicine In patient Erlotinib business medicine.drug |
Zdroj: | Journal of Clinical Oncology. 26:8031-8031 |
ISSN: | 1527-7755 0732-183X |
DOI: | 10.1200/jco.2008.26.15_suppl.8031 |
Popis: | 8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line failed to improve survival. Preclinical data suggested potential antagonism due to TKI-induced G1 arrest reducin... |
Databáze: | OpenAIRE |
Externí odkaz: |